Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Praluent Launch Brings Clinical Practice Challenges

Executive Summary

Despite enthusiasm about PCSK9 class, the prescribing community will have to wrestle with patient-selection criteria, uncertainty about very low LDL levels and a lack of outcomes data for Sanofi and Regeneron’s alirocumab.

You may also be interested in...

Sanofi's Praluent And Amgen's Repatha Now Set For Battle In Europe, US

Praluent and Repatha are ready for a transatlantic showdown after regulatory approvals in Europe and US, but the jury remains out on which PCSK9 inhibitor will gain the upper hand.

CVS Health Seeks Return To LDL Treatment Targets To Control PCSK9s

Broad nature of latest cholesterol treatment guidelines makes it hard to deploy utilization management programs to control use of pricey new PCSK9 inhibitors, CVS Health argues in JAMA editorial.

Praluent Coverage: Being First May Not Matter As Payers Await Repatha

The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts